The European Commission on Wednesday announced that Sanofi (SNY) has agreed to stop disparaging a rival flu vaccine developed by CSL Limited (CSLLY) after the French drugmaker faced an EU antitrust ...

CSL has bounced hard off its lows, and some are already buying back in. But one broker says it's his 'most likely to ...

Confidence has been shaken, but I think the long-term opportunity remains attractive. The post Is CSL a fallen ASX giant to ...

CSL Ltd (ASX: CSL) shares closed around 1% higher on Thursday afternoon, at $125.53 a piece. The increase continues the ...

When Fanatec revealed last year that it was bringing a direct drive wheel base to market for just $350, sim racers sort of lost it. Direct drive is the cream of the crop in terms of force feedback ...

After an antitrust review knocked 2021’s biggest biopharma buyout off course in May, CSL’s $11.7 billion deal for Swiss iron deficiency specialist Vifor Pharma appears to be back on track. Tuesday, ...

CSL's stunning fall has investors questioning its comeback prospects. The post Once untouchable, now unloved: What's up with CSL shares? appeared first on The Motley Fool Australia.

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. CSL has started construction ...

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...

It's been a sad week for CSL Limited (ASX:CSL), who've watched their investment drop 16% to AU$152 in the week since the company reported its interim result. Revenues came in 2.7% below expectations, ...